Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Uniqure N.v. (QURE)
since 2017 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Uniqure N.v..
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 1590560.
Total stock buying since 2017: $0.
Total stock sales since 2017: $49,150,891.
Total stock option exercises since 2017: $4,527,867.
Table 3. Detailed insider trading at Uniqure N.v. (QURE) , Part 2
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2020-12-16 | Kapusta Matthew C (CEO, CFO, Managing Director) | Option Ex | 12,501 | 7.53 | 94,132 |
| 2020-11-19 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 11,355 | 45.18 | 513,018 |
| 2020-11-19 | Kapusta Matthew C (CEO, CFO, Managing Director) | Option Ex | 3,125 | 7.53 | 23,531 |
| 2020-11-18 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 10,313 | 43.93 | 453,081 |
| 2020-11-18 | Kapusta Matthew C (CEO, CFO, Managing Director) | Option Ex | 3,216 | 7.53 | 24,216 |
| 2020-10-14 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 5,250 | 36.16 | 189,813 |
| 2020-09-21 | Gut Robert (Chief Medical Officer) | Sale | 4,352 | 39.12 | 170,250 |
| 2020-09-18 | Kuta Alexander Edward Iii (Executive VP, Operations) | Sale | 2,230 | 41.18 | 91,831 |
| 2020-09-16 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 7,500 | 41.28 | 309,622 |
| 2020-08-25 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 300 | 40.27 | 12,081 |
| 2020-08-19 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 4,300 | 39.45 | 169,635 |
| 2020-07-22 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 5,626 | 42.62 | 239,808 |
| 2020-06-23 | Gut Robert (Chief Medical Officer) | Sale | 26,875 | 70.00 | 1,881,250 |
| 2020-06-23 | Gut Robert (Chief Medical Officer) | Option Ex | 26,875 | 37.69 | 1,012,784 |
| 2020-06-17 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 7,501 | 66.33 | 497,563 |
| 2020-05-20 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 7,501 | 60.18 | 451,410 |
| 2020-04-24 | Klemt Christian (Chief Accounting Officer) | Sale | 2,250 | 60.00 | 135,000 |
| 2020-04-24 | Klemt Christian (Chief Accounting Officer) | Option Ex | 2,250 | 26.41 | 59,422 |
| 2020-04-22 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 9,376 | 57.07 | 535,088 |
| 2020-04-22 | Kapusta Matthew C (CEO, CFO, Managing Director) | Option Ex | 9,376 | 7.53 | 70,601 |
| 2020-03-18 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 5,626 | 42.03 | 236,460 |
| 2020-03-18 | Kapusta Matthew C (CEO, CFO, Managing Director) | Option Ex | 5,626 | 7.53 | 42,363 |
| 2020-03-04 | Klemt Christian (Chief Accounting Officer) | Sale | 15,750 | 53.00 | 834,750 |
| 2020-03-04 | Klemt Christian (Chief Accounting Officer) | Option Ex | 15,750 | 26.41 | 415,957 |
| 2020-02-19 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 7,501 | 64.52 | 483,949 |
| 2020-02-05 | Soteropoulos Paula (Director) | Sale | 2,122 | 61.05 | 129,558 |
| 2020-01-31 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 3,872 | 57.98 | 224,498 |
| 2020-01-30 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 23,583 | 59.97 | 1,414,272 |
| 2020-01-30 | Astley-sparke Philip (Director) | Sale | 807 | 59.23 | 47,798 |
| 2020-01-29 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 23,583 | 62.15 | 1,465,683 |
| 2020-01-28 | Springhorn Jeremy P. (Director) | Sale | 807 | 61.57 | 49,686 |
| 2020-01-28 | Gut Robert (Chief Medical Officer) | Sale | 596 | 62.19 | 37,065 |
| 2020-01-28 | Klemt Christian (Chief Accounting Officer) | Sale | 11,975 | 61.65 | 738,258 |
| 2020-01-28 | Kuta Alexander Edward Iii (Executive VP, Operations) | Sale | 1,478 | 61.62 | 91,066 |
| 2020-01-28 | Schaffer David (Director) | Sale | 806 | 62.27 | 50,189 |
| 2020-01-28 | Soteropoulos Paula (Director) | Sale | 807 | 62.19 | 50,187 |
| 2020-01-28 | Balachandran Madhavan (Director) | Sale | 807 | 62.20 | 50,195 |
| 2020-01-28 | Meek David D. (Director) | Sale | 722 | 61.57 | 44,453 |
| 2020-01-28 | Van Deventer Sander (EVP, Research & Product Dev.) | Sale | 2,227 | 61.69 | 137,372 |
| 2020-01-28 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 23,583 | 62.15 | 1,465,754 |
| 2020-01-28 | Kaye Jack (Director) | Sale | 806 | 62.20 | 50,133 |
| 2020-01-27 | Gut Robert (Chief Medical Officer) | Sale | 6,897 | 60.01 | 413,888 |
| 2020-01-27 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 28,289 | 63.53 | 1,797,143 |
| 2020-01-15 | Kuta Alexander Edward Iii (Executive VP, Operations) | Sale | 4,000 | 68.97 | 275,880 |
| 2020-01-15 | Kuta Alexander Edward Iii (Executive VP, Operations) | Option Ex | 4,000 | 5.31 | 21,240 |
| 2020-01-07 | Soteropoulos Paula (Director) | Sale | 3,000 | 72.18 | 216,540 |
| 2019-12-18 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 7,540 | 70.73 | 533,304 |
| 2019-12-18 | Kapusta Matthew C (CEO, CFO, Managing Director) | Option Ex | 7,339 | 7.53 | 55,262 |
| 2019-12-16 | Kuta Alexander Edward Iii (Executive VP, Operations) | Sale | 4,000 | 74.97 | 299,900 |
| 2019-12-16 | Kuta Alexander Edward Iii (Executive VP, Operations) | Option Ex | 4,000 | 5.31 | 21,240 |
| 2019-12-13 | Soteropoulos Paula (Director) | Sale | 2,000 | 70.50 | 141,000 |
| 2019-12-13 | Soteropoulos Paula (Director) | Option Ex | 2,000 | 5.37 | 10,740 |
| 2019-12-09 | Soteropoulos Paula (Director) | Sale | 2,500 | 67.50 | 168,750 |
| 2019-12-06 | Soteropoulos Paula (Director) | Sale | 9,082 | 64.04 | 581,611 |
| 2019-11-20 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 8,000 | 53.93 | 431,464 |
| 2019-11-15 | Kuta Alexander Edward Iii (Executive VP, Operations) | Sale | 4,000 | 52.34 | 209,360 |
| 2019-11-15 | Kuta Alexander Edward Iii (Executive VP, Operations) | Option Ex | 4,000 | 5.31 | 21,240 |
| 2019-10-23 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 8,000 | 43.30 | 346,360 |
| 2019-10-15 | Kuta Alexander Edward Iii (Executive VP, Operations) | Sale | 4,000 | 42.35 | 169,400 |
| 2019-10-15 | Kuta Alexander Edward Iii (Executive VP, Operations) | Option Ex | 4,000 | 5.31 | 21,240 |
| 2019-09-19 | Gut Robert (Chief Medical Officer) | Sale | 4,769 | 47.16 | 224,906 |
| 2019-09-18 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 8,000 | 47.59 | 380,760 |
| 2019-09-16 | Kuta Alexander Edward Iii (Executive VP, Operations) | Sale | 4,000 | 47.26 | 189,040 |
| 2019-09-16 | Kuta Alexander Edward Iii (Executive VP, Operations) | Option Ex | 4,000 | 5.31 | 21,240 |
| 2019-08-21 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 8,000 | 56.48 | 451,840 |
| 2019-08-01 | Astley-sparke Philip (Director) | Sale | 6,460 | 59.81 | 386,391 |
| 2019-07-17 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 8,000 | 71.34 | 570,744 |
| 2019-06-19 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 8,000 | 77.61 | 620,920 |
| 2019-06-03 | Astley-sparke Philip (Director) | Sale | 6,000 | 63.17 | 379,050 |
| 2019-05-15 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 8,000 | 58.40 | 467,176 |
| 2019-04-16 | Klemt Christian (Chief Accounting Officer) | Sale | 1,546 | 57.18 | 88,400 |
| 2019-04-01 | Astley-sparke Philip (Director) | Sale | 6,000 | 59.84 | 359,040 |
| 2019-03-14 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 19,688 | 63.52 | 1,250,522 |
| 2019-03-13 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 47,688 | 64.58 | 3,079,547 |
| 2019-02-15 | Kuta Alexander Edward Iii (SVP, Regulatory Affairs) | Sale | 8,000 | 36.20 | 289,600 |
| 2019-02-15 | Kuta Alexander Edward Iii (SVP, Regulatory Affairs) | Option Ex | 20,000 | 5.31 | 106,199 |
| 2019-01-28 | Springhorn Jeremy P. (Director) | Sale | 1,210 | 31.32 | 37,897 |
| 2019-01-28 | Mcmillan Scott T. (Chief Operating Officer) | Sale | 591 | 31.23 | 18,456 |
| 2019-01-28 | Klemt Christian (Chief Accounting Officer) | Sale | 1,479 | 31.29 | 46,277 |
| 2019-01-28 | Kuta Alexander Edward Iii (SVP, Regulatory Affairs) | Sale | 1,052 | 31.29 | 32,917 |
| 2019-01-28 | Schaffer David (Director) | Sale | 1,210 | 31.31 | 37,885 |
| 2019-01-28 | Soteropoulos Paula (Director) | Sale | 1,210 | 31.32 | 37,897 |
| 2019-01-28 | Balachandran Madhavan (Director) | Sale | 1,210 | 31.31 | 37,885 |
| 2019-01-28 | Van Deventer Sander (Chief Scientific Officer) | Sale | 1,358 | 31.31 | 42,518 |
| 2019-01-28 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 19,085 | 31.42 | 599,650 |
| 2019-01-28 | Astley-sparke Philip (Director) | Sale | 1,210 | 31.32 | 37,897 |
| 2019-01-28 | Kaye Jack (Director) | Sale | 1,210 | 31.31 | 37,885 |
| 2019-01-17 | Schaffer David (Director) | Sale | 7,500 | 30.71 | 230,325 |
| 2019-01-03 | Klemt Christian (Chief Accounting Officer) | Sale | 5,739 | 27.91 | 160,175 |
| 2018-12-03 | Astley-sparke Philip (Director) | Sale | 5,000 | 30.39 | 151,950 |
| 2018-06-06 | Zelenkofske Steven (Chief Medical Officer) | Sale | 23,929 | 37.14 | 888,723 |
| 2018-03-15 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 39,169 | 21.72 | 850,750 |
| 2018-01-29 | Schaffer David (Director) | Sale | 2,878 | 18.53 | 53,329 |
| 2018-01-29 | Soteropoulos Paula (Director) | Sale | 2,878 | 18.53 | 53,329 |
| 2018-01-29 | Van Deventer Sander (Chief Scientific Officer) | Sale | 5,985 | 18.53 | 110,902 |
| 2018-01-29 | Astley-sparke Philip (Director) | Sale | 6,540 | 18.53 | 121,186 |
| 2018-01-29 | Kaye Jack (Director) | Sale | 2,878 | 18.53 | 53,329 |
| 2018-01-04 | Kapusta Matthew C (CEO, CFO, Managing Director) | Sale | 21,690 | 19.87 | 431,067 |
| 2018-01-03 | Klemt Christian (Chief Accounting Officer) | Sale | 5,093 | 20.13 | 102,511 |
| 2018-01-03 | Garen Jonathan (Chief Business Officer) | Sale | 5,864 | 20.13 | 118,030 |
| 2018-01-03 | Firuta Paul E (Chief Commercial Officer) | Sale | 5,864 | 20.13 | 118,030 |
| 2018-01-03 | Cantor Maria E (SVP, Investor Relations & Comm) | Sale | 5,864 | 20.13 | 118,030 |
| 2017-06-29 | Petry Harald (Chief Scientific Officer) | Sale | 21,547 | 6.02 | 129,712 |
| 2017-06-29 | Petry Harald (Chief Scientific Officer) | Option Ex | 21,547 | 3.50 | 75,436 |
| 2017-06-28 | Petry Harald (Chief Scientific Officer) | Sale | 27,753 | 6.01 | 166,851 |
| 2017-06-28 | Petry Harald (Chief Scientific Officer) | Option Ex | 27,753 | 3.49 | 96,941 |
| 2017-06-27 | Petry Harald (Chief Scientific Officer) | Sale | 7,700 | 6.00 | 46,215 |
| 2017-06-27 | Petry Harald (Chief Scientific Officer) | Option Ex | 7,700 | 3.48 | 26,803 |
| 2017-06-26 | Petry Harald (Chief Scientific Officer) | Sale | 58,075 | 6.01 | 349,030 |
| 2017-06-26 | Petry Harald (Chief Scientific Officer) | Option Ex | 58,075 | 3.43 | 199,371 |
| 2017-06-22 | Petry Harald (Chief Scientific Officer) | Sale | 155 | 6.00 | 930 |
| 2017-06-22 | Petry Harald (Chief Scientific Officer) | Option Ex | 155 | 3.42 | 530 |
| 2017-03-21 | Petry Harald (Chief Scientific Officer) | Sale | 25,422 | 6.03 | 153,294 |
| 2017-03-21 | Petry Harald (Chief Scientific Officer) | Option Ex | 25,422 | 3.30 | 83,790 |
Insider trading activities including stock purchases, stock sales, and option exercises
of QURE listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Uniqure N.v. (symbol QURE,
CIK number 1590560) see
the Securities and Exchange Commission (SEC) website.